Vercher-Conejero JL. Quo Vadis, Teragnosis? Rev Esp Med Nucl Imagen Mol. 2022;41:341–343.
The era of theragnostics provides a great opportunity for improving patient care and it is clear that theragnostics will become an important pillar in the personalized treatment of cancer. We still have an unimaginable and exciting road ahead from which our specialty will reap the rewards. It is time to ask where theragnosis is going in nuclear medicine: Quo Vadis, theragnosis. A personal view by Spanish Oncidium foundation Ambassador Jose L Vercher Conejero on where nuclear medicine is headed, especially in the exciting field of theranostics.
2253-8089/© 2022 Sociedad Espa˜nola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa˜na, S.L.U. All rights reserved.